cigna glp-1 coverage news today reaches new deal on Eli Lilly and Novo Nordisk weight loss drugs Overview | Cigna Healthcare Newsroom

Recent data from the ATTAIN-MAINTAIN trial showed that patients transitioning to orforglipron after injectable GLP-1 therapy maintained their weight loss with minimal regain (approximately 0.9 kg after semaglutide transition), suggesting that oral maintenance strategies could minimize the lean mass depletion seen with prolonged high-dose injectable therapy

Abstract Obesity is a major public health crisis

Keeping a record of your past efforts can help support your case

Dr South said the risk appears to be greatest when people first start taking the medication, or when increasing their dosage, but that a significant delay in gastric emptying is not there a year down the track

Thus, metabolic changes may be key players in many disorders, including depression [91, 92]

Gastric bypass surgery attenuates ethanol consumption in ethanol-preferring rats